Ocumetics Technology Corp stock analysis
Ocumetics Technology Corp (2QB0) Stock Price & Analysis
2QB0 Stock Chart & Stats
- Day’s Range
- EUR 0.20 - EUR 0.20
- 52-Week Range
- EUR 0.20 - EUR 0.54
- Previous Close
- EUR 0.20
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 34.33M
- Enterprise Value
- EUR 63.76M
- Total Cash (Recent Filing)
- EUR 88.74K
- Total Debt (Recent Filing)
- EUR 4.31M
- Price to Earnings (P/E)
- ―
- Beta
- -0.34
- Next Earnings
- Dec 01, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmology Platform
A focused ophthalmology strategy gives the company a clearly defined product area and development objective. Concentrating resources on vision-correction technology may support specialized expertise and disciplined commercialization planning if the platform advances through clinical and regulatory stages.
Defined Product Target
The Bionic Lens provides a specific technology target rather than a broad or unfocused research program. If development and approvals progress, its intended role as an alternative to existing correction options could create a distinct commercial opportunity in ophthalmic implants.
Active Development Program
Continued research, regulatory preparation, and commercialization planning indicate that the company is maintaining a coordinated pathway toward potential product launch. This preserves the possibility of future operating scale, although success depends on advancing beyond development into commercial revenue.
Bears Say
No Commercial Revenue
Zero revenue shows that the business has not yet converted its technology program into commercial sales. Without an established revenue stream, funding for research, regulatory work, and operations must continue without internal sales support, making progress dependent on future commercialization.
Widening Losses
The widening net loss indicates that expenses are increasing faster than the company’s ability to generate income. Persistent and larger losses can consume capital over the next several quarters, reduce financial flexibility, and make eventual profitability more dependent on successful product commercialization.
Weak Capitalization And Cash Burn
Negative equity, substantial debt relative to assets, and ongoing cash burn create a fragile financial base. The company may need continued external funding to sustain operations, increasing financing and dilution risk while limiting its capacity to absorb delays in development or regulatory progress.
Ocumetics Technology Corp News
2QB0 FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
What is Ocumetics Technology Corp’s market cap?
When is Ocumetics Technology Corp’s upcoming earnings report date?
How were Ocumetics Technology Corp’s earnings last quarter?
Is Ocumetics Technology Corp overvalued?
Does Ocumetics Technology Corp pay dividends?
What is Ocumetics Technology Corp’s EPS estimate?
How many shares outstanding does Ocumetics Technology Corp have?
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
- Sector
- General
- Industry
- Medical - Instruments & Supplies
- CEO
- Dean E. Burns
- Employees
- 5
- Website
- ocumetics.com
- Address
- 639-5th Avenue SW, Calgary, AB, T2P 0M9, CA
Ocumetics Technology Corp (2QB0) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |










